Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

RCT (n=1085) reported that daratumumab plus bortezomib, thalidomide, and dexamethasone before and after autologous stem-cell transplantation improved depth of response and progression-free survival with acceptable safety.

The results were reported as follows:

More patients in the bortezomib, thalidomide, and dexamethasone alone and daratumumab group versus bortezomib, thalidomide, and dexamethasone alone achieved a stringent complete response by day 100 (primary endpoint, 29% vs 20%, respectively; OR 1.60; p=0.0010).